MedTrace Logo

HAL-MPE1 Safety and Tolerability Study

NCT02991885 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-02-19

No results posted yet for this study

Summary

The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.

Conditions

Interventions

BIOLOGICAL

HAL-MPE1

Weekly subcutaneous administrations of HAL-MPE1

DRUG

HAL-MPE1 placebo

Weekly subcutaneous administrations of HAL-MPE1 placebo

Sponsors & Collaborators

  • HAL Allergy

    lead INDUSTRY

Principal Investigators

  • Robert Wood, MD · John Hopkins Hospital Unversity-Divison of Pediatric Allergy

  • Scott Sicherer, MD · Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai

  • Edwin Kim, MD · UNC Rheumatolory Allergy & Immunology Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-04-30
Completion
2019-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991885 on ClinicalTrials.gov